PRELID3BP2

Across TCGA pan-cancer cohorts, PRELID3BP2 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated PRELID3BP2 data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher PRELID3BP2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PRELID3BP2 expression acts as an unfavorable survival marker.

STAD, OV, and KIRC are the cancer types where PRELID3BP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Tertile	II,III,IV	0.470	0.682	<.001	162	view →
OV	OS	Tertile	II,III,IV	0.321	0.845	<.001	108	view →
KIRC	OS	Tertile	All	0.208	0.633	<.001	84	view →
READ	OS	Tertile	All	0.685	0.932	.001	30	view →
KIRP	DFS	Tertile	All	0.157	0.867	<.001	27	view →
LGG	OS	Tertile	All	0.569	0.815	.023	12	view →
CHOL	OS	Tertile	All	0.155	0.725	.029	9	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PRELID3BP2–STAD (OS)

Open the STAD breakdown →